Laboratorios Farmaceuticos Rovi, S.A. (LON:0ILL)

Market Cap	2.80B
Revenue (ttm)	632.13M
Net Income (ttm)	105.75M
Shares Out	n/a
EPS (ttm)	2.07
PE Ratio	26.45
Forward PE	21.63
Dividend	0.66 (1.06%)
Ex-Dividend Date	Jul 14, 2025

Volume	814
Average Volume	17,140
Open	62.45
Previous Close	62.49
Day's Range	62.25 - 62.58
52-Week Range	45.58 - 66.55
Beta	0.44
RSI	61.28
Earnings Date	Feb 23, 2026

About LON:0ILL

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+,...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1946
• Employees: 2,197
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0ILL

Financial Performance

In 2024, LON:0ILL's revenue was 763.75 million, a decrease of -7.93% compared to the previous year's 829.51 million. Earnings were 136.88 million, a decrease of -19.64%.

Financial numbers in EUR